Skip to main content
SpringerLink
Log in

Low fixed dose pembrolizumab with gemcitabine, vinorelbine, liposomal doxorubicin (Pembro100 -GVD) as an effective salvage regimen in relapsed refractory classical hodgkin’s lymphoma and primary mediastinal B cell lymphoma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fakhri B, Ai W (2021) Current and emerging treatment options in primary mediastinal B-cell lymphoma. Ther Adv Hematol 12:20406207211048960. https://doi.org/10.1177/20406207211048959

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, Armand P, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Rodig SJ, Shipp MA (2016) PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J Clin Oncol 34(23):2690–2697. https://doi.org/10.1200/JCO.2016.66.4482

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Voorhees TJ, Beaven AW (2020) Therapeutic updates for relapsed and refractory classical hodgkin lymphoma. Cancers (Basel) 12(10):2887. https://doi.org/10.3390/cancers12102887

    Article  CAS  PubMed  Google Scholar 

  4. Collins GP, Parker AN, Pocock C, Kayani I, Sureda A, Illidge T, Ardeshna K, Linch DC, Peggs KS; British Committee for Standards in Haematology; British Society of Blood and Marrow Transplantation (2014) Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma. Br J Haematol 164(1):39–52. https://doi.org/10.1111/bjh.12582

  5. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH; KEYNOTE-087 (2017) Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol 35(19):2125–2132. https://doi.org/10.1200/JCO.2016.72.1316

  6. Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, Fogliatto L, Garcia-Sancho AM, Christian B, Gulbas Z, Özcan M, Perini GF, Ghesquieres H, Shipp MA, Thompson S, Chakraborty S, Marinello P, Armand P (2023) Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood 142(2):141–145

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, Matasar MJ, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD, Moskowitz CH (2021) Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical hodgkin lymphoma. J Clin Oncol 39(28):3109–3117. https://doi.org/10.1200/JCO.21.01056

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Jiang M, Hu Y, Lin G, Chen C (2022) Dosing Regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency, shorter course. Front Oncol 12:906251. https://doi.org/10.3389/fonc.2022.906251

Download references

Author information

Authors and Affiliations

  1. Department of Hemato-Oncology and Bone Marrow Transplant, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

    Tribikram Panda, Sujay Rainchwar, Rohan Halder, Reema Singh, Dinesh Bhurani & Narendra Agrawal

Authors
  1. Tribikram Panda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sujay Rainchwar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rohan Halder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Reema Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dinesh Bhurani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Narendra Agrawal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Narendra Agrawal.

Ethics declarations

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Competing interests

The authors have no competing interests to declare that are relevant to the content of this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Novelty statement

Low fixed dose pembrolizumab with GVD(Pembro100-GVD) is an effective, affordable chemo-immunotherapeutic salvage regimen for rrHL and rrPMBCL.

Specific clinical relevance

Limited cycles of low dose pembrolizumab based salvage therapies can be an effective regimen as bridge to transplant in rrHL and rrPMBCL.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Panda, T., Rainchwar, S., Halder, R. et al. Low fixed dose pembrolizumab with gemcitabine, vinorelbine, liposomal doxorubicin (Pembro100 -GVD) as an effective salvage regimen in relapsed refractory classical hodgkin’s lymphoma and primary mediastinal B cell lymphoma. Ann Hematol 103, 347–349 (2024). https://doi.org/10.1007/s00277-023-05470-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05470-5

Search

Navigation